Development and Validation of HPTLC Methods for Estimation of Trimebutine Maleate in Pharmaceutical Formulation
DOI:
https://doi.org/10.37591/(rrjops).v8i1.481Abstract
A simple and rapid high-performance thin-layer chromatographic (HPTLC) method was developed and validated for quantitative determination of trimebutine maleate in single dose formulation. Trimebutine maleate was chromatographed on silica gel 60 F 254 TLC plate using methanol–toluene (8:2 v/v) as mobile phase. The plates were developed to a distance of 8 cm at ambient temperature. Trimebutine maleate was quantified by densitometric analysis at 271 nm. The method was found to give compact spots for the drug (Rf=0.49± 0.01). The linear regression analysis data for the calibration plots showed good linear relationship with R² = 0.999 in the concentration range 50–300 ng/spot. The method was validated for precision, recovery, repeatability, and robustness as per the International Conference on Harmonization (ICH) guidelines. The minimum detectable amount was found to be 1.18 ng/spot, whereas the limit of quantitation was found to be 3.58 ng/spot. Statistical analysis of the data showed that the method is precise, accurate, reproducible, and selective for the analysis of trimebutine maleate.
Keywords: trimebutine maleate, high-performance thin-layer chromatography (HPTLC), validation
Cite this Article
Bhole RP, Jadhav D, Wankhede SB, et al. Development and Validation of HPTLC Methods for Estimation of Trimebutine Maleate in Pharmaceutical Formulation. Research and Reviews: A Journal of Pharmaceutical Science. 2017; 8(1): 17–22p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |